News Focus
News Focus
icon url

DewDiligence

06/29/17 10:07 AM

#212181 RE: DewDiligence #204974

FDA accepts BLA for Celltrion's Rituxan FoB:

http://www.koreabiomed.com/news/articleView.html?idxno=792

This is the first 351(k) application for an oncology mAb. If approved, TEVA will market the product in the US.